A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

This study assessed the safety and preliminary efficacy of escalated dose subcutaneous alemtuzumab in combination with rituximab in chronic lymphocytic leukemia. Twenty-eight patients with relapsed refractory chronic lymphocytic leukemia were treated on four dosing cohorts of weekly rituximab at 375...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Brown, Jennifer R., Messmer, Bradley, Werner, Lillian, Davids, Matthew S., Mikler, Evgeny, Supko, Jeffrey G., Fisher, David C., LaCasce, Ann S., Armand, Philippe, Jacobsen, Eric, Dalton, Virginia, Tesar, Bethany, Fernandes, Stacey M., McDonough, Sean, Ritz, Jerome, Rassenti, Laura, Kipps, Thomas J., Neuberg, Donna, Freedman, Arnold S.
Formato: Artigo
Idioma:Inglês
Publicado: Ferrata Storti Foundation 2013
Assuntos:
Original Articles and Brief Reports
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3669454/
https://ncbi.nlm.nih.gov/pubmed/23645694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2013.086207
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares